News

New research demonstrates the role of T cells and dendritic cells in patients with "cold" tumors resistant to standard treatment.

Scientists have shown that PD-L1 is a potential anti-cancer therapy target for the treatment of metastasized oral malignant melanoma in dogs.

A trial evaluating a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19.

Researchers have developed a new approach to gene editing using the CRISPR/Cas9 system. The method bypasses disease-causing mutations in a gene, enabling treatment of genetic diseases linked to a single gene, such as cystic fibrosis, certain types of sickle cell anemia, and other rare diseases.

Researchers have developed technology that allows microbes to produce drugs with feedback control systems, dialing down or amping up protein concentration as needed.

Research indicates that organ tissues become increasingly immune throughout life, which may begin to alter fundamental ideas regarding the rules of vaccination and the immune system's function within the body.

A team from the University of Colorado Boulder has created a drug development platform that can produce effective and highly specific peptide nucleic acid therapies for use against any bacteria within just one week.

According to a clinical trial, a new gene therapy for one of the most common forms of congenital blindness was safe and improved patients’ vision.

A Purdue University chemist has discovered a way to synthesize a rare compound found in a shrub native to North America, to fight a previously "undruggable" cancer protein implicated in numerous cancer types.

The large, randomized, placebo‑controlled Phase 3 clinical trial will explore up to seven drugs approved by US Food and Drug Administration (FDA) for other conditions – an approach called drug repurposing – and test their safety and effectiveness in treating mild-to-moderate COVID-19.